Drug Database
CS

CSF-G

✓ Approved

Dong-A ST · CSF3R · 重组蛋白

什么是 CSF-G?

CSF-G 是一种重组蛋白,由Dong-A ST研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

公司Dong-A ST
药物类别重组蛋白
分子靶点CSF3R
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

CSF-G 作用于 1 个分子靶点:

CSF3Rcolony stimulating factor 3 receptor (CD114, GCSFR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

CSF-G 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Blood and lymphatic system disordersNeutropenia✓ Approved

相关研究文献

PubMedThe Cochrane database of systematic reviews2026-11-17

Prophylactic granulopoiesis-stimulating factors for people with solid tumors undergoing cancer treatment.

Ma Mina M, Yang Minyan M, Wu Yanan Y, Li Wenjing W et al.

Many chemotherapy agents used in the treatment of solid tumors can induce myelosuppression, resulting in hematologic toxicities such as neutropenia and febrile neutropenia (FN), which are major causes of treatment-related morbidity and mortality. Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) are well-established stimulators of myelopoiesis and hematopoietic stem cell mobilization. Although previous reviews have suggested improved overall survival among individuals receiving intensified chemotherapy supported by primary G-CSF, it remains unclear whether prophylactic administration of G-CSF or GM-CSF itself improves overall survival, freedom from treatment failure (FFTF), or FN-associated complications when compared with placebo or no prophylaxis under the condition of identical treatment regimens. To assess the efficacy of prophylactic granulopoiesis-stimulating factors compared with placebo or no prophylaxis on survival outcomes and preventing adverse effects of cancer treatment in people with solid tumors. We searched CENTRAL, MEDLINE, and Embase and ongoing trials registers, together with reference checking, in June 2025. There were no restrictions on language or publication status. We included randomized controlled trials (RCTs) comparing primary granulopoiesis-stimulating factors with placebo or no prophylaxis in participants aged 18 years and older with solid tumors. Our outcomes were overall survival, FFTF, risk of infection, quality of life, all-cause mortality during chemotherapy, risk of bone pain, and duration of hospitalization. We used Cochrane's RoB 1 tool to assess risk of bias in the included studies. We synthesized results for each outcome using meta-analysis where possible. We assessed statistical heterogeneity between studies using a Chi2 test and I2 values. We used hazard ratios (HRs) with 95% confidence intervals (CIs) for time-to-event data and risk ratios (RRs) with 95% CIs for dichotomous outcomes. We used GRADE to assess the certainty of evidence for each outcome. We included 26 RCTs with a total of 5320 participants. We assessed two trials as having a high risk of bias, and the remaining studies as having a low or unclear risk of bias. Primary prophylaxis G-CSF or GM-CSF compared with control likely results in a reduction in risk of infection (RR 0.64, 95% CI 0.49 to 0.83; P = 0.001; 7 studies, 915 participants; moderate-certainty evidence), but may result in little to no difference in overall survival (HR 0.85, 95% CI 0.28 to 2.54; P = 0.59; 3 studies, 537 participants; low-certainty evidence) and FFTF (HR 0.89, 95% CI 0.63 to 1.25; P = 0.50; 1 study, 259 participants; low-certainty evidence). Primary prophylaxis G-CSF or GM-CSF compared with control likely results in little to no difference in all-cause mortality during chemotherapy (RR 0.92, 95% CI 0.53 to 1.60; P = 0.75; 11 studies, 3001 participants; moderate-certainty evidence). Regarding adverse events, primary prophylaxis G-CSF compared with control probably results in a large increase in risk of bone pain (RR 3.55, 95% CI 1.09 to 11.56; P = 0.04; 10 studies, 3152 participants; moderate-certainty evidence), a clinically important adverse outcome. One study reported that participants in the GM-CSF group had a significantly longer mean hospitalization duration (9.7 days versus 5.2 days, P < 0.01). Quality of life was not reported in any of the included studies. There is moderate-certainty evidence that primary prophylaxis G-CSF or GM-CSF likely reduces risk of infection versus control. In contrast, low- to moderate-certainty evidence suggests little to no improvement in overall survival and FFTF, and likely little to no difference between groups in all-cause mortality during chemotherapy. Regarding adverse events, moderate-certainty evidence shows a likely large increase in risk of bone pain. Data on the effects of prophylaxis G-CSF or GM-CSF compared to control on duration of hospitalization were inadequate to draw any conclusions, and no studies evaluated quality of life. We identified no new ongoing studies, and the number of recent publications is limited. Further research in this field is warranted. This Cochrane review was funded by the "Innovation Star" project of outstanding graduate students in Gansu Province (2023CXZX-142), China. Protocol was available via 10.1002/14651858.CD015656.

PMID 43042756
阅读全文 →
PubMedStem cell research & therapy2026-11-17

The critical role of cerebrospinal fluid-contacting neurons in spinal cord injury repair mediated by treadmill training.

Tan Wei W, Shangguan Zeyu Z, Shi Xuexing X, Li Qizhe Q et al.

Adult neural stem cells play a significant role in promoting motor function recovery after spinal cord injury (SCI) through rehabilitative exercise. However, it remains unclear whether cerebrospinal fluid-contacting neurons (CSF-cNs), which possess the potential to act as neural stem cells, are involved in treadmill training-facilitated SCI repair. This study aimed to investigate the role of CSF-cNs in this process. Treadmill training was performed on female C57BL/6 mice with SCI to assess the activation and proliferation of CSF-cNs with neural stem cell potential. The effects of treadmill training on axonal growth, myelin regeneration, tissue repair, and motor function recovery were evaluated. To further validate the role of CSF-cNs in exercise-induced spinal cord repair, Pkd2l1-/- mice exhibiting CSF-cNs depletion underwent treadmill training after SCI, and the resulting changes in neural stem cell proliferation and spinal cord repair were assessed. Treadmill training activated the neural stem cell potential of CSF-cNs, promoted their proliferation, and was accompanied by enhanced axon growth, myelin regeneration, and motor function recovery. In contrast, a significant reduction in proliferating cells around the central canal of the spinal cord was observed in Pkd2l1-/- mice. Furthermore, deletion of Pkd2l1 significantly attenuated the beneficial effects of treadmill training on motor function recovery in SCI mice. CSF-cNs play a critical role in SCI recovery enhanced by treadmill training. These findings highlight the potential of CSF-cNs as a therapeutic target for the development of novel strategies to treat SCI.

PMID 43040556
阅读全文 →
PubMedInfection and drug resistance2026-11-17

Clinical Characteristics and Interpretive Challenges of CSF Varicella-Zoster Virus Detection by Metagenomic Next-Generation Sequencing: A Retrospective Case Series.

Wei Yan Y, Wang Xuyi X, Yu Weitong W, Zhao Chenxi C et al.

Varicella-zoster virus (VZV) may cause heterogeneous central nervous system (CNS) manifestations, often without a typical herpes zoster rash. Metagenomic next-generation sequencing (mNGS) enables broad pathogen detection in cerebrospinal fluid (CSF), but VZV reads may be difficult to interpret when additional microorganisms are detected or confirmatory testing is incomplete. This study described the clinical characteristics and interpretive challenges of patients with suspected CNS infection in whom VZV was detected in CSF by mNGS. This retrospective descriptive case series included patients evaluated at The Second Qilu Hospital of Shandong University from January 2019 to December 2024. Among 278 patients with suspected CNS infection who underwent CSF mNGS, 23 met the prespecified operational inclusion criteria. Clinical, CSF, neuroimaging, microbiological, treatment, and short-term outcome data were reviewed. Detected microorganisms were interpreted through integrated clinical assessment rather than sequencing findings alone. No comparison group was included. VZV reads meeting the inclusion criteria were detected in 23 of 278 patients (8.3%). The median age was 44 years, and 15 patients (65.2%) were male. Clinical syndromes spanned encephalitis, meningitis, meningoencephalitis, encephalomyelitis, and myelitis. A herpes zoster-associated rash was present in 10 patients (43.5%). All patients had CSF leukocytosis with lymphocytic predominance, and 21 (91.3%) had elevated CSF protein. VZV-specific polymerase chain reaction was not performed. Qualitative CSF anti-VZV IgM and IgG testing was performed in six patients, of whom two had positive IgM results. Additional microorganisms were co-detected in six patients, including Epstein-Barr virus, low-abundance herpes simplex virus type 1, and Listeria monocytogenes. The median Karnofsky Performance Status score at discharge was 90 (interquartile range, 90-100), with three patients (13.0%) scoring below 90. VZV detection by CSF mNGS occurred across heterogeneous neurological presentations, sometimes alongside additional microorganisms. VZV reads alone cannot establish pathogen causality, and their clinical significance requires integrated assessment of the neurological syndrome, CSF findings, neuroimaging, conventional microbiological investigations, immune status, co-detected microorganisms, and clinical course. The findings are descriptive and do not establish the diagnostic accuracy of mNGS.

PMID 43042328
阅读全文 →
PubMedVeterinary evidence2026-11-17

Diagnostic accuracy of cerebrospinal fluid pleocytosis in suspected meningoencephalomyelitis of unknown origin in canines.

Horowitz Zachary Z

In canines with suspected meningoencephalomyelitis of unknown origin (MUO) [population], does cerebrospinal fluid analysis for pleocytosis [intervention], compared with histopathology [comparison], accurately identify underlying noninfectious inflammatory central nervous system (CNS) disease [outcome]? Diagnosis. Three retrospective case series and one systematic review. Moderate. The four studies included collectively reported the presence or absence of cerebrospinal fluid (CSF) pleocytosis in dogs with histopathologically confirmed noninfectious inflammatory CNS disease or clinically diagnosed MUO where applicable. Pleocytosis is defined as a total nucleated cell count (TNCC) above the laboratory reference interval. The first study reported pleocytosis in all 22 dogs evaluated with granulomatous meningoencephalomyelitis (GME). In contrast, the second paper identified normal TNCC in a substantial proportion of GME cases, a finding mirrored by the third study across a significant number of GME, necrotising meningoencephalitis (NME), and clinically diagnosed MUO patients. Finally, the fourth study documented normal repeat CSF TNCC levels in a single dog with progressive NME within a small sample size. Cerebrospinal fluid pleocytosis supports a diagnosis of noninfectious inflammatory CNS disease in dogs with suspected MUO but does not exclude disease when absent. Furthermore, CSF findings cannot reliably distinguish between inflammatory disease subtypes. Therefore, CSF analysis should be interpreted alongside neurological examination, magnetic resonance imaging (MRI) findings, and exclusion of infectious diseases rather than used as a standalone diagnostic test. How to apply this evidence in practice The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient's circumstances and owners' values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.

PMID 43042094
阅读全文 →
PubMedASN neuro2026-11-17

TUBB2A as a Candidate Therapeutic Target for Alzheimer's Disease: Orotidine-Mediated Metabolic Mechanisms and Druggability.

Liang Liling L, Zhang Jingjing J, Zhang Ying Y

As the most prevalent neurodegenerative disorder, Alzheimer's disease (AD) poses a pressing need for novel therapeutic targets. This study was designed to address this gap by screening and validating druggable genetic targets nominally associated with AD through an integrative multi-omics approach. Mendelian randomization (MR) screened the druggable genome. GTEx eQTL data and differential expression analysis identified core candidates. SMR, GSMR, and cross-tissue eQTL validation assessed putative causal effects and cross-tissue generalizability. Single-cell RNA sequencing (scRNA-seq) dissected cell type-specific expression. Virtual knockout combined with cell-cell communication analysis elucidated regulatory mechanisms. Mediation analysis evaluated Cerebrospinal fluid (CSF) metabolite involvement, and molecular docking screened therapeutic agents. Genetically predicted TUBB2A expression was nominally associated with AD risk. Virtual knockout analysis revealed that TUBB2A deficiency induced significant upregulation of SLC1A3 and HIF3A, suggesting compensatory glutamate clearance and hypoxic stress responses. Nominal mediation analysis suggested that the CSF metabolite orotidine may be involved in the TUBB2A-AD association. Molecular docking revealed high binding affinity between Eribulin mesylate and TUBB2A. This study identifies TUBB2A as a priority candidate gene for further validation in AD, proposes a potential role for orotidine in TUBB2A-related AD susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies. susceptibility, and identifies eribulin mesylate as a potential therapeutic agent worthy of further investigation, thereby generating testable hypotheses for future mechanistic and therapeutic studies.

PMID 43042626
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-11-17

Synthesis of Curved Nanoplatelet Graphite From Calcium Carbide and Amorphous Carbon at Low Temperature.

Zhang Chunyan C, Ran Mingxin M, Yuan Kailing K, Hu Yi Y et al.

Artificial graphite requires high temperature and high pressure conditions, which leads to high energy consumption and cost in its production. This study proposes a new low-temperature oxidative-reductive graphitization technology, which involves converting amorphous carbon and carbon elements in calcium carbide into graphite. Glucose hydrothermal carbon spheres (CS), citric acid pyrolysis carbon (CA) and biomass bamboo pyrolysis carbon (BB) have been converted into curved nanoplatelet graphite, and the potential graphitization mechanism has been discussed. The experimental results show that the samples prepared at 1100°C possess both a high degree of graphitization and excellent performance as lithium-ion battery anodes. The graphitized carbon GCCS-3 prepared from calcium carbide and CS achieves 441 mA h g-1 at a current density of 0.1 A g-1, remains at 183.3 mA h g-1 at 5 A g-1, and the capacity reaches 412.1 mA h g-1 after 500 cycles at a current density of 1 A g-1. This technology provides an efficient and simple solution for amorphous carbon graphitization and lithium anode material optimization.

PMID 43042710
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多CSF-G